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Summary
Tuberous sclerosis complex (TSC) is an autosomal dominant multisystem hereditary cutaneous condition, characterized 
by multiple hamartomas. In rare cases, pituitary neuroendocrine tumors (PitNETs) have been described in patients with 
TSC, but the causal relationship between these two diseases is still under debate. TSC is mostly caused by mutations of 
two tumor suppressor genes, encoding for hamartin (TSC1) and tuberin (TSC2), controlling cell growth and proliferation. 
Here, we present the case of a 62-year-old Caucasian woman with TSC and a silent gonadotroph PitNET with suprasellar 
extension, treated with transsphenoidal endoscopic neurosurgery with complete resection. Therapeutic approaches 
based on mTOR signaling (i.e. everolimus) have been successfully used in patients with TSC and tested in non-functioning 
PitNET cellular models with promising results. Here, we observed a reduction of cell viability after an in vitro treatment of 
PitNET’s derived primary cells with everolimus. TSC analysis retrieved no disease-associated variants with the exception of 
the heterozygous intronic variant c.4006-71C>T found in TSC2: the computational tools predicted a gain of a new splice 
site with consequent intron retention, not confirmed by an in vitro analysis of patient’s lymphocyte-derived RNA. Further 
analyses are therefore needed to provide insights on the possible mechanisms involving the hamartin-tuberin complex in 
the pathogenesis of pituitary adenomas. However, our data further support previous observations of an antiproliferative 
effect of everolimus on PitNET.
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 • Pituitary neuroendocrine tumors (PitNET) in patients with tuberous sclerosis complex (TSC) are rare: only few cases 
have been reported in literature.
 • Therapeutic approach related to mTOR signaling, such as everolimus, may be used in some patients with PitNETs 
as well as those with TSC.
 • We reported a woman with both non-secreting PitNET and TSC; PitNET was surgically removed and classified as a 
silent gonadotroph tumor.
 • Everolimus treatment in PitNET’s-derived primary cells revealed a significant decrease in cell viability.
 • Considering our case and available evidence, it is still unclear whether a PitNET is a part of TSC or just a 
coincidental tumor.
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Tuberous sclerosis complex (TSC) is an autosomal 
dominant multisystem hereditary cutaneous condition, 
characterized by multiple hamartomas that can be 
associated to endocrine system alterations (1, 2). TSC 
is mostly caused by mutations of two tumor suppressor 
genes TSC1 and TSC2, encoding for hamartin and tuberin, 
respectively. In normal cells, hamartin and tuberin form 
a molecular complex involved in intracellular signaling 
pathways controlling cell growth and proliferation, 
including the mammalian target of rapamycin (mTOR) 
cascade. Therapeutic approach related to mTOR signaling, 
such as everolimus, may be used in some patients (1, 2).
In nearly 10% of cases mutations are mosaic or 
intronic and a comprehensive genotype–phenotype 
correlation is still debatable. About two thirds of TSC 
cases are sporadic reflecting a high spontaneous mutation 
rate in these genes (3).
Some reports addressing PitNET in TSC patients 
suggest the possible involvement of pituitary gland 
alterations in the pathological process of TSC (4). The 
development of pituitary tumors by nearly half of adult 
Eker rats – i.e. spontaneous germline TSC2 mutants – 
further supports this possible association (5). Up to now, 
however, no molecular evaluation of PitNET in patients 
with TSC has been performed to establish the weight 
of this link and whether PitNET should be considered 
a clinical manifestation of TSC is far from being clearly 
understood.
Case presentation
Here we present the case of a 62-year-old Caucasian 
woman whose diagnosis of TSC was made after the 
recognition of cognitive disability and neurobehavioral 
abnormalities of her only 32-year-old son, developed 
since childhood. She presented the typical TSC brain 
lesions at MRI (i.e. cortical tuber and right retinal 
hamartoma) without other typical TSC-related 
manifestations (e.g. renal, pulmonary, cardiac or skin 
lesions) and no family history of TSC. During the last 
20 years she refused medical care, but in April 2012, she 
complained of headache: MRI scan showed a PitNET (size: 
20 × 18 × 16 mm) with suprasellar extension, bilateral 
cavernous sinus invasion, shortened pituitary stalk and 
left optic nerve compression (Fig. 1A). Clinically, she had 
central obesity, moon face, congenital left blindness and 
a normal right visual field. A hormonal study revealed 
normal thyroid and adrenal function, low gonadotropins 
(LH: 3.5 U/L, range: 11–61; FSH: 13.5 U/L, range: 
35–150) and elevated prolactin (75.7–74–79 µg/L, range: 
5–25, probably due to shortened pituitary stalk). After 
4  months, she underwent transsphenoidal endoscopic 
neurosurgery with complete tumor resection. Histologic 
evaluation demonstrated a uniform PAS-positive 
basophilic adenoma with low proliferation index (MIB-1: 
<3%). Immunohistochemistry was positive for FSH and 
LH (Fig. 1B and C) and negative for ACTH, GH, prolactin 
and TSH. Clinical and histological findings were thus 
consistent with a silent gonadotroph PitNET.
Investigation
Neurosurgery is the first treatment choice for PitNET 
(6), especially for those non-functioning, which are still 
orphans of medical therapy. Reduction of cell viability 
as a consequence of an increased apoptosis has been 
reported after an in vitro treatment of non-secreting 
PitNET with everolimus and its possible use in patients 
has been suggested (7). Given the therapeutic potential of 
everolimus in TSC (1) and PitNETs (7) – both conditions 
Figure 1
(A) Brain T1-weighted MRI after gadolinium injection: pituitary 
macroadenoma with suprasellar extension and bilateral cavernous sinus 
invasion; Immunohistochemical analysis of (B) FSH (20× magnification) 
and (C) LH (40× magnification) expression in the tissue slice of the silent 
gonadotroph PitNET (D) and standard hematoxylin-eosin staining.
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present in our patient – primary cells derived from her 
pituitary adenoma were cultured in vitro (5000 cell/well 
in a 96 wells plate) and treated with everolimus (0.1 
and 1 µM, kindly provided by Novartis) for evaluating 
its pharmacological effect. After 72-h treatment, the 
conversion of the tetrazolium dye MTT (Sigma-Aldrich) 
to formazan was ascertained following manufacturer 
protocol. After media removal and the addition of DMSO, 
the solution’s absorbance was measured at 550 nm – 
background subtraction set at 620 nm – with a microplate 
reader (Victor3 V 1420 Multilabel 206 Counter, Perkin 
Elmer). Treatment with 1μM induced a significant 20% 
decrease in cell viability (P < 0.05), confirming previous 
reported data (7) (Fig. 2A).
To search for the TSC disease-causative variant 
– and possibly associate it with pituitary adenoma 
development – patient’s germline DNA was isolated from 
the peripheral blood and the genomic analysis of the 
entire TSC1 (NM_000368.4) and TSC2 (NM_000548.3) 
coding sequence and intronic boundaries was performed. 
The analysis retrieved no disease-associated variants 
with the exception of the heterozygous intronic variant 
c.4006-71C>T found in TSC2 (Fig.  2B) and not present 
either in dbSNP or in ExAC databases. The computational 
tools MutationTaster and Human Splicing Finder both 
predicted a gain of a new splice site with consequent 
intron retention that was, however, not confirmed by 
an in vitro analysis of patient’s lymphocyte-derived RNA. 
In addition, molecular analysis on archived paraffin-
embedded pituitary tumoral tissues failed to identify both 
loss of heterozygosity in TSC2 locus (Fig. 2B) and protein 
expression reduction (Fig. 2C), as expected if this would 
have been a loss-of-function mutation involved in the 
pathogenesis of this silent gonadotroph PitNET.
Treatment
We described the treatment in the intervention paragraph.
Outcome and follow-up
Pituitary imaging (with magnetic resonance) has been 
performed yearly, without evidence of a recurrent pituitary 
adenoma. The last visit was performed in May 2018.
Discussion
As far as we know, this is the first attempt to evaluate by 
a molecular approach the involvement of a TSC-related 
gene variant in the pathogenesis of the PitNET in a TSC 
patient. Considering the c.4006-71C>T variant causative 
for TSC – that is reasonable given the frequency of intronic 
mutations in TSC (i.e. 5%) (3) and its absence in the 
normal population – we could exclude the involvement of 
pituitary gland alterations in the pathological process of 
TSC, at least in this patient. On the other hand, however, 
until functional data on this variant has not been 
gathered, we cannot exclude possible alternative genetic 
mechanisms causative of TSC including mosaic mutations 
in TSC1 regulatory regions – the mosaicism would easily 
explain the mild phenotype of our patient (3) – or an 
additional TSC causative gene. Nearly 10–15% of TSC 
patients lack, indeed, a conclusive molecular diagnosis (1, 
2). Although relevant, our data are thus not conclusive 
for establishing unequivocally the causal nature of the 
association between TSC and PitNET that might only 
be a coincidence due to the relative high prevalence of 
pituitary tumors in the general population (8).
Although everolimus has been successfully tested in 
non-functioning and growth hormone-secreting PitNET 
cellular models (7, 9, 10), very few data are available 
on its use in PitNET patients. Everolimus has indeed 
been used for treating only two patients with pituitary 
carcinomas resistant to repeated resections, radiations 
and combined treatment with chemotherapeutic agents – 
i.e. Temozolomide and Capecitabine – with limited effects 
(11, 12). Our data corroborate the efficacy of everolimus 
in reducing cell viability in non-secreting PitNET and 
Figure 2
(A) Effects of everolimus treatment on pituitary 
tumor primary cells viability; (B) 
Electropherograms centered on the c.4006-71C>T 
variant both in germline (upper panel) and 
tumoral (lower panel) DNA; (C) 
immunohistochemical analysis of Tuberin 
expression (40× magnification) in the tissue slice 
of the silent gonadotroph PitNET (D93F12, XP 
Rabbit mAb of Cell Signaling at 1:100 dilution 
after microwave antigen retrieval in 10 mM 
citrate pH6.0).
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support the need of further studies for demonstrating its 
efficacy and safety for treating this group of tumors.
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